Du LSD ou de l’ecstasy pour traiter la maladie mentale La thérapie psychédélique a pour principe d’aider les gens à adopter un nouveau regard sur leur santé et leur mode de vie. Alexis Riopel 10 décembre 2018 https://www.ledevoir.com/societe/sante/543271/science-du-lsd-ou-de-l-ecstasy-pour-traiter-la-maladie-mentale Un cachet, une séance, des effets qui perdurent. Grosso modo, telle est la promesse des psychiatres qui travaillent sur le développement de traitements recourant à des drogues psychédéliques pour soigner des troubles de santé mentale. Plutôt que d’apaiser les symptômes de la maladie mentale, ces substances servent à « reconnecter » le cerveau. Si elles étaient légalisées dans un contexte médical — et c’est ce qui semble en [...]
Lire la suiteNeuropathology of Drug Addictions and Substance Misuse Volume 2: Stimulants, Club and Dissociative Drugs, Hallucinogens, Steroids, Inhalants and International Aspects 2016, Pages 773-781 Chapter 72 - Use of LSD by Mental Health Professionals Petr Winkler, Ingmar Gorman, Rita Kočárová Doi : 10.1016/B978-0-12-800212-4.00072-8 Abstract This chapter focuses on self-experimentation with hallucinogens within the mental health sciences. Emphasis is given to the use of LSD by mental health professionals in the former Czechoslovakia. The text is based on four main data sources: (1) interviews with mental health professionals who experimented with LSD on themselves in the former Czechoslovakia; (2) scientific articles that were published in the time LSD research [...]
Lire la suiteMDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials Michael C. Mithoefer, Allison A. Feduccia, Lisa Jerome, Anne Mithoefer, Mark Wagner, Zach Walsh, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, Rick Doblin Psychopharmacology, 2019 https://doi.org/10.1007/s00213-019-05249-5 Abstract Background : Posttraumatic stress disorder is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment options. Here we evaluate six phase 2 trials in a pooled analysis to determine the study design for phase 3 trials of MDMA-assisted psychotherapy for PTSD. Methods : Six randomized, double-blind, controlled clinical trials [...]
Lire la suiteEfficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study Vanina Popova, M.D., Ella J. Daly, M.D., Madhukar Trivedi, M.D., Kimberly Cooper, M.S., Rosanne Lane, M.A.S., Pilar Lim, Ph.D., Christine Mazzucco, M.Sc., David Hough, M.D., Michael E. Thase, M.D., Richard C. Shelton, M.D., Patricio Molero, M.D., Ph.D., Eduard Vieta, M.D., Ph.D., Malek Bajbouj, M.D., Husseini Manji, M.D., Wayne C. Drevets, M.D., Jaskaran B. Singh, M.D. American Journal of Psychiatry in Advance, 2019 ajp.psychiatryonline.org doi: 10.1176/appi.ajp.2019.19020172 Objective : About one-third of patients with depression fail to achieve remission despite treatment with multiple [...]
Lire la suitePsychedelic therapy in the Czech Republic : A theoretical concept or a realistic goal ? Zuzana Postranecka, Čestmir Vejmola and Filip Tyls Journal of Psychedelic Studies DOI: 10.1556/2054.2019.003 Abstract Psychedelic research has been associated with the Czech Republic since the early 19th century and, after a long period of involuntary dormancy, it has recently gained new opportunities to follow up on its roots and evolve. This article briefly describes the history of psychedelic research in the Czech Republic, summarizes the role of the UN Drug Conventions, and discusses the Czech and international legislation pertaining to psychedelics. The discussion focuses on the dependence/abuse potential of classical [...]
Lire la suiteRapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression : a randomized placebo-controlled trial Fernanda Palhano-Fontes, Dayanna Barreto, Heloisa Onias, Katia C. Andrade, Morgana M. Novaes, Jessica A. Pessoa, Sergio A. Mota-Rolim, Flávia L. Osório, Rafael Sanches, Rafael G. dos Santos, Luís Fernando Tófoli, Gabriela de Oliveira Silveira, Mauricio Yonamine7, Jordi Riba, Francisco R. Santos, Antonio A. Silva-Junior, João C. Alchieri10, Nicole L. Galvão-Coelho5,11, Bruno Lobão-Soares5,12, Jaime E. C. Hallak, Emerson Arcoverde, João P. Maia-de-Oliveira and Dráulio B. Araújo Psychological Medicine, June 2018, 1-9 https://www.cambridge.org/core doi.org/10.1017/S0033291718001356 Abstract Background. Recent open-label trials show that psychedelics, such as ayahuasca, hold promise as fast-onset antidepressants in treatment-resistant depression. Methods. [...]
Lire la suiteAcid Diethylamide (LSD) in the Treatment of Addictions: Historical Perspectives and Future Prospects Mitchell B. Liester Current Drug Abuse Reviews, 2014, 7, 146-156 1874-4745/14 $58.00+.00 © 2014 Bentham Science Publishers Abstract : Lysergic acid diethylamide (LSD) is a semisynthetic compound with strong psychoactive properties. Chemically related to serotonin, LSD was initially hypothesized to produce a psychosislike state. Later, LSD was reported to have benefits in the treatment of addictions. However, widespread indiscriminate use and reports of adverse affects resulted in the classification of LSD as an illicit drug with no accepted medical use. This article reviews LSD’s storied history from its discovery, to its use [...]
Lire la suiteThe alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro Jose A. Morales-García, Mario de la Fuente Revenga, Sandra Alonso-Gil, María Isabel Rodríguez-Franco, Amanda Feilding, Ana Perez-Castillo & Jordi Riba Scientific Reports, 2017, 7, 5309 www.nature.com/scientificreports https://www.nature.com/articles/s41598-017-05407-9 DOI:10.1038/s41598-017-05407-9 Abstract : Banisteriopsis caapi is the basic ingredient of ayahuasca, a psychotropic plant tea used in the Amazon for ritual and medicinal purposes, and by interested individuals worldwide. Animal studies and recent clinical research suggests that B. caapi preparations show antidepressant activity, a therapeutic effect that has been linked to hippocampal neurogenesis. Here we report that harmine, tetrahydroharmine and harmaline, the [...]
Lire la suite3,4-Methylenedioxymethamphetamine assisted psychotherapy for treatment of chronic posttraumatic stress disorder : A randomized phase 2 controlled trial Marcela Ot’alora G, Jim Grigsby, Bruce Poulter1, Joseph W Van Derveer III, Sara Gael Giron, Lisa Jerome, Allison A Feduccia, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, Michael C Mithoefer and Rick Doblin Journal of Psychopharmacology, 2018, 1-13 Doi : 10.1177/0269881118806297 Abstract Background : Posttraumatic stress disorder often does not resolve after conventional psychotherapies or pharmacotherapies. Pilot studies have reported that 3,4-methylenedioxymethamphetamine (MDMA) combined with psychotherapy reduces posttraumatic stress disorder symptoms. Aims : This pilot dose response trial assessed efficacy and safety of MDMA-assisted psychotherapy across multiple therapy teams. Methods : [...]
Lire la suiteA Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy Ben Sessa, Laurie Higbed and David Nutt Frontiers in Psychiatry, 2019, Vol. 10, article 138 DOI : 10.3389/fpsyt.2019.00138 Neuropsychopharmacology Unit, Department of Medicine, Imperial College London, London, United Kingdom Abstract : This paper provides a brief review of the history, proposed pharmacological mechanisms, safety issues, and clinical applications of the medicine 3,4-methylenedioxymethamphetamine (MDMA). Most clinical MDMA research in patients to date has focused on MDMA-assisted psychotherapy to treat posttraumatic stress disorder (PTSD). In this review paper other potential therapeutic applications for MDMA therapy are described, including contemporary studies treating anxiety associated with autism and the authors’ ongoing study exploring the potential [...]
Lire la suite